Citadel Advisors
RYTM icon

Citadel Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Citadel Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.11M Sell
28,000
-2,500
-8% -$226K ﹤0.01% 5635
2026
Q1 		$2.65M Sell
30,500
-7,400
-20% -$720K ﹤0.01% 5504
2025
Q4 		$4.06M Sell
37,900
-13,300
-26% -$1.41M ﹤0.01% 4621
2025
Q3 		$5.17M Buy
51,200
+33,800
+194% +$3.14M ﹤0.01% 4304
2025
Q2 		$1.1M Sell
17,400
-18,400
-51% -$1.13M ﹤0.01% 6888
2025
Q1 		$1.9M Sell
35,800
-94,500
-73% -$5.24M ﹤0.01% 5632
2024
Q4 		$7.29M Buy
130,300
+83,300
+177% +$4.6M ﹤0.01% 3384
2024
Q3 		$2.46M Buy
47,000
+3,500
+8% +$168K ﹤0.01% 5138
2024
Q2 		$1.79M Sell
43,500
-22,900
-34% -$914K ﹤0.01% 5533
2024
Q1 		$2.88M Sell
66,400
-7,500
-10% -$328K ﹤0.01% 4866
2023
Q4 		$3.4M Buy
73,900
+55,600
+304% +$1.75M ﹤0.01% 4442
2023
Q3 		$420K Buy
18,300
+2,600
+17% +$58.2K ﹤0.01% 8456
2023
Q2 		$259K Sell
15,700
-16,400
-51% -$296K ﹤0.01% 9341
2023
Q1 		$573K Sell
32,100
-13,100
-29% -$329K ﹤0.01% 8043
2022
Q4 		$1.32M Sell
45,200
-161,600
-78% -$4.15M ﹤0.01% 6293
2022
Q3 		$5.07M Sell
206,800
-9,900
-5% -$184K ﹤0.01% 3842
2022
Q2 		$899K Buy
216,700
+21,400
+11% +$117K ﹤0.01% 7263
2022
Q1 		$2.25M Buy
195,300
+184,100
+1,644% +$1.62M ﹤0.01% 5827
2021
Q4 		$112K Sell
11,200
-1,500
-12% -$16.9K ﹤0.01% 12606
2021
Q3 		$166K Buy
+12,700
New +$194K ﹤0.01% 12235
2021
Q2 		– Sell
-14,200
Closed -$302K – 14320
2021
Q1 		$302K Sell
14,200
-4,400
-24% -$128K ﹤0.01% 10843
2020
Q4 		$553K Buy
18,600
+1,100
+6% +$28K ﹤0.01% 7948
2020
Q3 		$379K Buy
+17,500
New +$401K ﹤0.01% 7757

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors's RYTM Position: Q2 2026 in Review

Citadel Advisors reduced its Rhythm Pharmaceuticals (RYTM) stake by 11% in Q2 2026, selling an estimated $14M and leaving 1,263,652 shares worth $140M. The position accounts for 0.02% of the portfolio, ranked #742.

Citadel Advisors first reported a position in RYTM in Q4 2017 and has held it in 26 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Citadel Advisors held 1,263,652 shares of Rhythm Pharmaceuticals worth $140M as of Q2 2026.
  • Citadel Advisors sold 154,967 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $14M.
  • Rhythm Pharmaceuticals made up 0.02% of Citadel Advisors's portfolio in Q2 2026, its #742 holding.
  • Citadel Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 26 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.